갑상선암 진단 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the thyroid cancer diagnostics market size in 2026 is estimated at USD 260.94 billion, growing from 2025 value of USD 245.08 billion with 2031 projections showing USD 357.01 billion, growing at 6.47% CAGR over 2026-2031.

This report is Segmented by Cancer Type (Papillary Carcinoma, Follicular Carcinoma, and More), Diagnostic Technique (Imaging, Blood-Based Biomarkers, and More), End User (Hospital Laboratories, Cancer Diagnostic Centers, Independent Reference Labs, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Thyroid Cancer Diagnostics Market Trends and Insights

Rising Incidence from Improved Imaging Sensitivity

AI-enabled ultrasound probes now detect sub-centimeter nodules with 89% accuracy, narrowing the gap between community clinics and tertiary centers. Siemens Healthineers' Acuson Sequoia platform adds automated organ labeling, cutting scan-to-report time and driving referral rates to endocrine surgeons. Increased sensitivity boosts biopsy volume, which lifts utilization of genomic classifiers and liquid biopsy tests that follow in the diagnostic cascade. While earlier capture fuels revenue, clinicians remain vigilant about over-diagnosis and overtreatment, spurring adoption of risk-stratification algorithms that flag indolent lesions for active surveillance instead of immediate surgery.

Government-Led Thyroid Cancer Screening & Awareness Programs

National initiatives in China, Japan and South Korea incorporate thyroid palpation and ultrasound into multi-cancer campaigns, standardizing referral pathways and lifting testing adherence. Japan's Cancer Center publishes granular incidence maps that guide mobile screening vans toward underserved prefectures. Mandatory reporting feeds regional cancer registries, creating large datasets that validate AI triage models. Screening regulations typically reference guideline-endorsed molecular panels, putting pressure on local laboratories to acquire NGS workflows. The programs' long-term funding ensures recurring demand while encouraging manufacturers to localize production for cost efficiencies.

Shortage of Skilled Endocrine Cytopathologists

Anatomic pathology vacancy rates rise annually; only 3.0% of U.K. laboratories meet recommended staffing levels. The shortage lengthens biopsy-to-report cycles and delays treatment decisions. Hospitals adopt cloud-based AI slide reviewers from Roche to triage low-risk smears, yet confirmatory reads still need board-certified experts. Training programs expand fellowship seats, but incumbents face retirement cliffs, extending the constraint well into the next decade.

Other drivers and restraints analyzed in the detailed report include:

1. Rapid Adoption of NGS-Based Genomic Classifiers
2. Expanding Reimbursement for Molecular Tests in OECD Markets
3. High Out-Of-Pocket Cost for Advanced Molecular Panels

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Papillary carcinoma generated the bulk of testing demand, holding 79.65% of the thyroid cancer diagnostics market in 2025. This dominance ensures steady baseline volume for ultrasound, cytology and NGS classifiers. Papillary lesions present favorable outcomes, so clinicians increasingly deploy molecular risk panels to spare low-risk patients from surgery, channeling them to active surveillance instead. Anaplastic carcinoma, despite accounting for less than 2% of incidence, drives a 7.88% CAGR by necessitating broad genomic profiling and liquid biopsy monitoring for rapid therapeutic adjustments. RET-fusion positivity now guides use of selpercatinib, which in turn mandates companion diagnostics at diagnosis and relapse.

The thyroid cancer diagnostics market size for rare subtypes such as medullary and follicular carcinoma is projected to scale steadily on the back of calcitonin assays and core-needle biopsy adoption. Follicular lesions still evade cytology, so ThyroSeq and Afirma uptake is brisk in endocrine clinics. Targeted testing for RET and RAS mutations refines prognostication and follow-up strategies, widening the overall serviceable market. Rising investigator-initiated trials for kinase inhibitors further entrench comprehensive genomic profiling across all histologies, sustaining long-term revenue.

Complete Report Scope:

• By Cancer Type
  • Papillary Carcinoma
  • Follicular Carcinoma
  • Medullary Carcinoma
  • Anaplastic Carcinoma
  • Other Cancer Types
• By Diagnostic Technique
  • Imaging
    • Ultrasound
    • CT / MRI
    • PET / SPECT
  • Blood-Based Biomarkers
    • TSH / T4 / T3 Panel
    • Thyroglobulin & Anti-Tg
    • Calcitonin / CEA
  • Tissue Biopsy
    • Fine-Needle Aspiration Cytology
    • Core Needle Biopsy
  • Liquid Biopsy
  • Other Diagnostic Techniques
• By End User
  • Hospital Laboratories
  • Cancer Diagnostic Centers
  • Independent Reference Labs
  • Other End Users
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Europe
    • Germany
    • United Kingdom
    • France
    • Spain
    • Italy
    • Russia
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America generated 38.74% of 2025 revenue, cementing its status as the largest regional contributor to the thyroid cancer diagnostics market. Medicare's MolDX coverage and private payer alignment underpin broad access, while U.S. clinical guidelines promote molecular classifiers for Bethesda III-V nodules. Canada covers ultrasound and cytology through provincially funded plans but reimburses genomic sequencing selectively, creating mixed public-private demand. Mexico improves urban oncology services through federal investment, although rural disparities persist. The region's innovation ecosystem propels AI model development, with GE HealthCare and NVIDIA co-engineering real-time ultrasound triage that mitigates pathologist shortages.

Asia-Pacific posts the fastest 7.90% CAGR. China's tiered cancer screening initiatives embed thyroid ultrasound in community clinics, escalating specimen submission to regional molecular hubs. Japan's population-based registry supports precision screening thresholds that reduce unnecessary biopsies yet ensure high testing volume where risk is elevated. India's rapid expansion of private oncology chains increases access to NGS panels, although pricing remains a hurdle. South Korea's insurance-backed check-up culture produces high scan rates, encouraging AI start-ups to commercialize triage platforms domestically before seeking U.S. Food and Drug Administration (FDA) clearance. The thyroid cancer diagnostics market share in Asia-Pacific will grow as local manufacturers release cost-optimized sequencing kits.

Europe maintains mature uptake of advanced diagnostics, guided by the European Medicines Agency's centralized review that clarifies companion-diagnostic pathways. Germany pilots nationwide AI ultrasound quality registries, while the United Kingdom's National Health Service (NHS) uplifts genomic classifier adoption through the Genomic Medicine Service. Southern European nations accelerate procurement of hybrid PET/MRI scanners, supported by EU recovery funds. Pan-European reimbursement parity remains a work in progress; however, collaborative procurement reduces per-unit reagent costs, benefiting smaller member states. These dynamics collectively boost the thyroid cancer diagnostics market, albeit at lower relative growth than Asia-Pacific.

1. Abbott Laboratories
2. Thermo Fisher Scientific
3. Eli Lilly and Company
4. Siemens Healthineers
5. GE Healthcare
6. Bio-Rad Laboratories
7. Agilent Technologies
8. Koninklijke Philips
9. Roche
10. Illumina
11. Daiichi Sankyo
12. Quest Diagnostics
13. Veracyte
14. Guardant Health
15. Myriad Genetics
16. Exact Sciences
17. Fulgent Genetics
18. Hologic
19. Thyrocare Technologies
20. Beckton Dickinson
21. PerkinElmer

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Incidence Due To Improved Imaging Sensitivity
  • 4.2.2 Government-Led Thyroid Cancer Screening & Awareness Programs
  • 4.2.3 Rapid Adoption Of NGS-Based Genomic Classifiers
  • 4.2.4 Expanding Reimbursement for Molecular Tests in OECD Markets
  • 4.2.5 AI-Driven Ultrasound Triage Tools in Primary Care
  • 4.2.6 Shift Toward PET/MRI Hybrid Restaging Protocols
• 4.3 Market Restraints
  • 4.3.1 Shortage Of Skilled Endocrine Cytopathologists
  • 4.3.2 High Out-Of-Pocket Cost for Advanced Molecular Panels
  • 4.3.3 Guideline Pushback on Over-Diagnosis & Active-Surveillance Preference
  • 4.3.4 Regulatory Uncertainty for AI Decision-Support Algorithms
• 4.4 Regulatory Landscape
• 4.5 Porter's Five Forces Analysis
  • 4.5.1 Threat of New Entrants
  • 4.5.2 Bargaining Power of Buyers
  • 4.5.3 Bargaining Power of Suppliers
  • 4.5.4 Threat of Substitutes
  • 4.5.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, 2024-2030)

• 5.1 By Cancer Type
  • 5.1.1 Papillary Carcinoma
  • 5.1.2 Follicular Carcinoma
  • 5.1.3 Medullary Carcinoma
  • 5.1.4 Anaplastic Carcinoma
  • 5.1.5 Other Cancer Types
• 5.2 By Diagnostic Technique
  • 5.2.1 Imaging
    • 5.2.1.1 Ultrasound
    • 5.2.1.2 CT / MRI
    • 5.2.1.3 PET / SPECT
  • 5.2.2 Blood-Based Biomarkers
    • 5.2.2.1 TSH / T4 / T3 Panel
    • 5.2.2.2 Thyroglobulin & Anti-Tg
    • 5.2.2.3 Calcitonin / CEA
  • 5.2.3 Tissue Biopsy
    • 5.2.3.1 Fine-Needle Aspiration Cytology
    • 5.2.3.2 Core Needle Biopsy
  • 5.2.4 Liquid Biopsy
  • 5.2.5 Other Diagnostic Techniques
• 5.3 By End User
  • 5.3.1 Hospital Laboratories
  • 5.3.2 Cancer Diagnostic Centers
  • 5.3.3 Independent Reference Labs
  • 5.3.4 Other End Users
• 5.4 Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 South America
    • 5.4.2.1 Brazil
    • 5.4.2.2 Argentina
    • 5.4.2.3 Rest of South America
  • 5.4.3 Europe
    • 5.4.3.1 Germany
    • 5.4.3.2 United Kingdom
    • 5.4.3.3 France
    • 5.4.3.4 Spain
    • 5.4.3.5 Italy
    • 5.4.3.6 Russia
    • 5.4.3.7 Rest of Europe
  • 5.4.4 Asia-Pacific
    • 5.4.4.1 China
    • 5.4.4.2 Japan
    • 5.4.4.3 India
    • 5.4.4.4 Australia
    • 5.4.4.5 South Korea
    • 5.4.4.6 Rest of Asia-Pacific
  • 5.4.5 Middle East & Africa
    • 5.4.5.1 GCC
    • 5.4.5.2 South Africa
    • 5.4.5.3 Rest of Middle East & Africa
  • 5.4.6 South America
    • 5.4.6.1 Brazil
    • 5.4.6.2 Argentina
    • 5.4.6.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Abbott
  • 6.3.2 Thermo Fisher Scientific, Inc.
  • 6.3.3 Eli Lilly & Company
  • 6.3.4 Siemens Healthineers
  • 6.3.5 GE HealthCare
  • 6.3.6 Bio-Rad Laboratories
  • 6.3.7 Agilent Technologies
  • 6.3.8 Koninklijke Philips
  • 6.3.9 F. Hoffmann-La Roche Ltd
  • 6.3.10 Illumina
  • 6.3.11 Daiichi Sankyo
  • 6.3.12 Quest Diagnostics
  • 6.3.13 Veracyte
  • 6.3.14 Guardant Health
  • 6.3.15 Myriad Genetics
  • 6.3.16 Exact Sciences
  • 6.3.17 Fulgent Genetics
  • 6.3.18 Hologic
  • 6.3.19 Thyrocare Technologies
  • 6.3.20 Becton, Dickinson & Co.
  • 6.3.21 PerkinElmer

7 Market Opportunities & Future Outlook

• 7.1 White-Space & Unmet-Need Assessment